best glp-1 for fatty liver Why are agonists being used to treat patients with nonalcoholic disease? Does GLP-1 Help Fatty Liver?

Description

A retrospective analysis of 105,000+ patients revealed: 40% lower OSA risk with tirzepatide (Zepbound) or semaglutide (Wegovy) vs non-AOM users Lower OSA incidence: 3.12% vs 12.56% Comparable impact between tirzepatide and semaglutide, with tirzepatide showing a slight edge after 6 months This study highlights the potential for AOMs to address obesity and OSA, supporting broader healthcare value through comorbidity reduction

GLP-1 receptor agonists are known to suppress appetite, which can lead to a reduced intake of essential micronutrients

These ingredients have been studied for their ability to help manage glucose metabolism, support digestion, and maintain a healthy inflammatory response